Import Clearance, Tax and Market Entry Structure: How to Design Them

1. Key takeaways

Once the CMDN or CMDR has been issued, import clearance requires the licensed entity LTO and the product registration certificate to be presented to Customs. Verification at the border is carried out by the Bureau of Customs, while the FDA uses the public health warning mechanism to require Customs to intercept unregistered products. The design question for market entry is structural: how the holding entity, the importing entity and the distributing entity are arranged determines control, tax cost and risk allocation.

• Two gates, not one: registration is the first gate, clearance is the second, and passing the first does not guarantee the second.
• Documents at the border: a valid LTO whose activity includes importation, plus a valid product certificate.
• Public verification: certificate status is visible to customs, tender committees and hospitals through the Verification Portal.
• Structure first: the entry model should be designed together with the holding model, not after the channel is fixed.

2. Legal basis

The prohibition on unauthorised importation sits in the parent statute, and the enforcement mechanism that connects the FDA to Customs and to local government sits in the advisory system. The table below records both, together with the documents that must be producible at the port.

3. Expert insights

First insight: clearance is the second gate, not an automatic consequence of registration. Many manufacturers assume that a certificate means they can ship. At the border, Customs verifies four things: whether the licensed entity holds a valid LTO, whether the LTO activity includes importation, whether the product certificate is valid, and whether the label carries the registration number. Failure on any one point results in the consignment being held. GRZAN recommends a clearance pack self-check before the first shipment, covering the LTO copy, the certificate copy, the commercial invoice, the packing list and the label specimen. The check takes an hour and prevents demurrage, storage charges and the commercial damage of a missed launch date.

Second insight: FDA enforcement works as a three-part mechanism of advisory, circulation and interception. A public health warning shows the full chain. The FDA identifies a problem through post-market surveillance, issues the public health warning, copies it simultaneously to law enforcement agencies and local government units, requires the Bureau of Customs to intercept entry, and opens the matter to public reporting through the eSumbong channel. The effect is that visibility in the distribution chain is high: an unregistered product, or one whose certificate has lapsed, is difficult to keep in circulation for long, because the parties who would encounter it include competitors, hospital procurement officers and the public. For a compliant manufacturer the mechanism is helpful, since it removes illegitimate competition; for an unregistered importer it closes the usual routes to a quiet market entry.

Third insight: there are three typical market entry structures, and their control profiles differ sharply. The first is a subsidiary holding the certificate, importing directly and distributing through third parties, which gives the strongest control at the highest fixed cost. The second is an independent third party holding the certificate and importing, with distribution appointed by the manufacturer, which balances control against cost and leaves the manufacturer free to replace distributors. The third is the distributor holding the certificate, importing and distributing on its own account, which is the cheapest to establish, leaves the least control, and carries the highest exit cost. The choice returns to the criteria set out in article 32: product line importance, intended length of operation and channel strategy. The structural error to avoid is deciding the channel first and then retrofitting the holding arrangement to it.

Fourth insight: certificate status is publicly verifiable, and expiry immediately affects both clearance and tenders. The FDA repeatedly directs the public and procurement bodies to check registration numbers through the Verification Portal. The consequence is that once a certificate expires or is suspended, clearance, bidding and hospital purchasing are affected at the same time. These are three separate commercial processes that depend on one administrative fact. A certificate lapse discovered during a tender is not a compliance inconvenience but a lost contract, and it is usually discovered by the buyer rather than by the manufacturer. GRZAN advises building a monthly certificate status self-check into routine post-market compliance so that the fact is monitored by the party with the strongest interest in it.

4. Practical recommendations

• Run a clearance pack self-check before the first shipment. LTO, registration certificate, invoice, packing list and label specimen, assembled and checked as one set.
• Confirm that the LTO activity includes importation. Only an LTO of the distributor type, covering importer, exporter or wholesaler activity, supports importation.
• Print the registration number on the label in the format shown on the certificate. A mismatch is a common cause of interception at the port.
• Institute a monthly certificate status check. Verify through the Verification Portal rather than relying on internal records.
• Design the entry structure and the holding structure together. Do not fix the channel first and work backwards to the licensing arrangement.

5. Verification checklist

• □ LTO valid and the activity type includes importation, as stated on the LTO certificate
• □ Product registration certificate valid when checked on the Verification Portal
• □ Label carries the correct registration number, checked against the certificate
• □ Clearance pack complete: LTO, certificate, invoice, packing list and label specimen
• □ Holding and importing entity arrangement documented in the agreement structure
• □ Monthly certificate status check scheduled in the project calendar

How GRZAN can help. GRZAN provides medical device and IVD registration, quality system, authorised representative and local testing support across Southeast Asia, including the Philippines. Our team prepares CMDN/CMDR dossiers to ASEAN CSDT structure, manages submissions and deficiency responses with the FDA Philippines, and supports post-market vigilance obligations. Business enquiries: info@grzanglobal.com